52 results
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
to be authorized or required by law to
remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders … or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
addition capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Ordinary Shares could render more
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
and credits are estimated at contract inception and updated at the end of each reporting period if additional information becomes available.
Employee … to the employee. According to IFRS 2, accounting for a modification to the terms of a share-based payment scheme, requires two valuations:
1
6-K
EX-99.2
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
traded company. In addition, we incurred severance costs of $93,561 with the departure of a certain employee. For the six months ended September 30, 2023
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Current report (foreign)
4:06pm
Director may be remunerated by the Company for the services he provides for the benefit of the Company, whether as Director, employee or otherwise … direct or indirect); and
(b) a trustee of an employee or retirement benefits scheme or other trust in which any of the persons referred
424B3
ahnzutta1psg4ydd 06
20 Dec 23
Prospectus supplement
4:03pm
F-3
b1gburv9i42
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.4
va3mc9n2c0q9z
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
4h6 fhj9mjmz9vxxxy
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.1
vptojhk
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-10.1
1yl3e0sf
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-4.1
5b73 6jxx
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
s8um3ja
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-10.1
vlz4c665ccu1sk0t56
18 Nov 22
Current report (foreign)
5:20pm
6-K
EX-10.1
um8irln3xl8bu833d
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
20-F
de1nj
12 Aug 22
Annual report (foreign)
4:20pm
6-K
EX-1.1
7t74ykns2n 8i7y5nuy
26 Jul 22
Current report (foreign)
7:36am